Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001214659-23-017033
Filing Date
2023-12-28
Accepted
2023-12-28 17:10:11
Documents
1
Period of Report
2023-12-01

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-63939.html 4  
1 PRIMARY DOCUMENT marketforms-63939.xml 4 25382
  Complete submission text file 0001214659-23-017033.txt   26816
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2525 WEST END AVENUE, SUITE 950 NASHVILLE TN 37203
Business Address
Young Caroline (Reporting) CIK: 0001684087 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 231523427